The Middle East systemic inflammatory response syndrome treatment market is set to grow from USD 1.19 billion in 2025 to USD 2.23 billion by 2035, driven by rising critical care demand, improving healthcare infrastructure, and advancements in treatment protocols, at a CAGR of 6.50%.

Middle East Systemic Inflammatory Response Syndrome Treatment Market Statical Scope

The Middle East Systemic Inflammatory Response Syndrome Treatment market size was estimated at USD 1.19 billion in 2025 and is expanding at a CAGR of 6.50 % from 2026 to 2035. The market growth is driven by expanding investment in healthcare infrastructure and growing access to critical care treatments across the developing healthcare systems.

Middle East Systemic Inflammatory Response Syndrome Treatment Market Share, By Indication, 2025 (%)

• Infectious causes - Infectious Causes lead the segment, with a share of 58%, driven by the high prevalence of sepsis and infection-related inflammatory responses, along with the increasing incidence of bacterial and viral diseases.
• Non-infectious causes - Non-infectious Causes hold a significant portion, with a share of 27%, supported by rising cases of trauma, burns, and pancreatitis triggering systemic inflammation.

Middle East Systemic Inflammatory Response Syndrome Treatment Market Share, By Mode of administration, 2025 (%)

• Injectable - Injectable dominates the segment, with a share of 72%, driven by the need for rapid onset of action and immediate management in critical care and emergency settings.
• Oral - Oral holds a smaller portion, with a share of 28%, supported by its use in less severe cases and for follow-up or maintenance therapy.

Middle East Systemic Inflammatory Response Syndrome Treatment Market Share, By End-user, 2025 (%)

• Hospital & Ambulatory Surgical Centers - Hospital & Ambulatory Surgical Centers dominate the segment, with a share of 78%, driven by the advanced medical infrastructure, emergency response, critical care and advanced treatment facilities.
• Specialty Clinics - Specialty Clinics hold a significant portion, with a share of 22%, supported by increasing outpatient care and specialized treatment services.

Middle East Systemic Inflammatory Response Syndrome Treatment Market Share, By Product Type, 2025 (%)

• Urinary Tract Infection (UTI) - Urinary Tract Infection (UTI) holds a notable share, with a share of 17%, supported by rising infection rates and complications contributing to systemic conditions.
• Autoimmune Diseases - Autoimmune Diseases account for a considerable share, with a share of 20%, driven by the increasing prevalence of immune-related disorders causing inflammatory responses.

North Middle East Systemic Inflammatory Response Syndrome Treatment Market Share, By Application, 2025 (%)

• Hospital & Ambulatory Surgical Centers - Hospital & Ambulatory Surgical Centers dominate the segment, with a share of 75%, driven by high patient inflow requiring critical and emergency care management.
• Specialty Clinics - Specialty Clinics hold a significant portion, with a share of 18%, supported by growing demand for specialized and follow-up treatments.

Top Companies in the Middle East Systemic Inflammatory Response Syndrome Treatment Market

• GlaxoSmithKline
• AstraZeneca
• CytoSorbents Corporation
• Cardinal Health
• Asahi Kasei
• ConvaTec
• CHIESI Farmaceutici
• Smith & Nephew

Segments Covered in the Report

By Indication

• Infectious causes
• Non-infectious causes
• UTI

By Mode of administration

• Injectable
• Oral

By End-user

• Hospital and ambulatory surgical centers
• Speciality Clinics

By Product Type

• Urinary Tract Infection (UTI)
• Autoimmune Diseases
• Meningitis
• Pneumonia
• Others

By Application

• Specialty Clinics
• Hospital & Ambulatory Surgical Centers
• Others